Tu1446: THE EFFICACY AND SAFETY OF GUSELKUMAB INDUCTION THERAPY IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: PHASE 2B QUASAR STUDY RESULTS THROUGH WEEK 12
Jessica R. Allegretti(Brigham and Women's Hospital), Axel Dignaß(Goethe University Frankfurt), William J. Sandborn(University of San Diego), Gary R. Lichtenstein, Tadakazu Hisamatsu(Kyorin University), Julián Panés(Hospital Clínic de Barcelona), Brian G. Feagan(Western University), David T. Rubin(University of California System), Brian Bressler(University of British Columbia), Nicole Shipitofsky(Janssen (United States)), Kuan‐Hsiang Gary Huang(Janssen (United States)), Jewel Johanns(Johnson & Johnson (United States)), Matthew Germinaro(Johnson & Johnson (United States)), Hongyan Zhang(Northwest A&F University), Bruce E. Sands(Icahn School of Medicine at Mount Sinai)
Cited by 0
Related Papers
Infliximab for Induction and Maintenance Therapy for Ulcerative Colitis
|New England Journal of Medicine|2005|3.9k
Vedolizumab as Induction and Maintenance Therapy for Ulcerative Colitis
|New England Journal of Medicine|2013|2.9k
Dysfunction of the intestinal microbiome in inflammatory bowel disease and treatment
|Genome biology|2012|2.8k
Vedolizumab as Induction and Maintenance Therapy for Crohn's Disease
|New England Journal of Medicine|2013|2.7k